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Introduction
============

Induction of labor is defined as any intervention performed with the aim of inducing labor before a spontaneous onset of labor. Labor induction is a common obstetric procedure, but it is also described as "one of the most drastic ways of intervening in the natural process of pregnancy and childbirth".^[@R1](p375)^ Historically, labor induction has been performed to terminate progressing pathological conditions that could potentially harm mother or fetus, such as preeclampsia, intrauterine growth restriction or diabetes.^[@R2]^ Over the last decades, however, induction rates have increased two- to four-fold in the developed world,^[@R3]-[@R5]^ and the World Health Organization (WHO) estimates that 25% of women in developed countries have their labor induced.^[@R3]^ There seems to be no single reason for the increase. Suggested explanations include the availability of cervical ripening agents, an increasing demand from patients and a shift in professional clinical culture towards increased use of interventions in childbirth.^[@R5],[@R6]^ Even though healthcare interventions are usually performed with the intention to improve the health of the patient, interventions are also prone to iatrogenic mechanisms, where the intervention itself can cause harm.^[@R1],[@R7]^ This may be an overlooked element in current maternity care, and there is a lack of knowledge on the benefits and harms following a more liberal use of labor induction among large groups of low-risk pregnancies.

Current induction rates do not correspond with WHO recommendations, which emphasize that labor induction should be performed only when there is a clear medical indication and the expected benefits outweigh potential harms; studies suggest that 25--50% of inductions are performed without a medical reason.^[@R8]-[@R11]^ Of these, many are inductions that are performed prior to post-term. A pregnancy is defined as post-term when it reaches two completed weeks past estimated due date (EDD).^[@R5],[@R12]^ In these cases, mother and fetus are healthy when induction is initiated, and the intervention is made as a precautionary treatment to prevent potential fetal demise or fetal death.

Elective induction after EDD may be beneficial in regards to risks imposed by the ongoing pregnancy, such as the progress of adverse conditions in pregnancy (e.g. pre-eclampsia, oligohydramnios, macrosomia), shoulder dystocia, postpartum hemorrhage, asphyxia, meconium aspiration syndrome, neonatal birth injury, low umbilical artery pH, admission to neonatal intensive care unit, or intrauterine fetal demise, which can develop into fetal death.^[@R6],[@R13]^ On the other hand, labor induction has also been found to be an independent risk factor for birth complications and associated with increased fetal and maternal morbidity and possibly also mortality.^[@R2],[@R14],[@R15]^ Iatrogenic effects (iatrogenesis or iatrogenic effect is a Greek term meaning "brought forth by the healer" and defined as any consequence of medical treatment or advice to a patient)^[@R7]^ of induced labor include longer labor, uterine hyperstimulation, precipitate labor, uterine ruptures, meconium stained liquid, bleeding, and fetal asphyxia.^[@R16]^ In addition, induced labor can cause a cascade of interventions, such as continuous electronic fetal monitoring, amniotomy, confinement to bed due to fetal monitoring or intravenous treatment and increased requirement for analgesia (e.g. epidural), each with their own individual risk of potential subsequent complications.^[@R16]^

Between approximately the 1980s to the mid-2000s, obstetric textbooks and influential obstetric medical societies recommended close fetal surveillance and/or labor induction, when a pregnancy exceeded 14 days past EDD. In contrast to other mammals, humans may go into spontaneous labor over a wide window of time. Hence, term delivery is defined as occurring over a time span of five weeks, i.e. between 37 and 42 gestational weeks (GW) (259--293 gestational days), and a post-term delivery is defined as occurring at 42 GW or later.^[@R5],[@R12],[@R17]^ During 2008--2010 both the UK and the US obstetric societies and the WHO changed the recommended gestational timing for induction from two weeks past EDD to one week past EDD in order to reduce adverse conditions, especially cases of intrauterine death due to fetal demise.^[@R3],[@R17]-[@R19]^ This shift occurred as part of a general trend towards increased medicalization of pregnancy and childbirth, and today inductions are widely performed as a routine medical procedure before the pregnancy exceeds 14 days past EDD.^[@R20]^ However, concerns have been raised that routine induction prior to post-term puts a large number of normal pregnancies at risk of iatrogenic effects from the induction.^[@R11],[@R21],[@R22]^ It is estimated that 15--24% of pregnant women have not yet gone into spontaneous labor or given birth at 41 weeks and zero days (41+0 GW), and that most of them are likely to do so within the following week. Hence, in settings where routine induction is not offered until after 42 GW, it has been found that only 1--6% have not gone into spontaneous labor by 42+0 GW.^[@R23],[@R24]^ This suggests that induction prior to post-term leads to a substantially increased number of inductions in low-risk pregnant women and, thus, imposes possible additional complications related to the intervention itself upon a large group of low-risk pregnancies. Additionally, this could be more costly because of increased need of care and longer hospital stays.^[@R25],[@R26]^

Research has been carried out to explore the benefits and harms of changed guidelines from routine induction of labor two weeks past EDD to only one week past EDD. However, existing evidence suffers from a lack of consensus as to which groups to compare in studies on routine labor induction after EDD. This means that current clinical guidelines are based on studies (including meta-analyses) with varying comparison group definitions. For example, some studies compare routine induction one week past EDD with groups that are defined by unlimited time for the maximum length of pregnancy, e.g. four weeks past EDD.^[@R27],[@R28]^ This diminishes the relevance of the findings, because it is far from current obstetric practice and because the risk of severe adverse maternal and fetal outcomes is largely increased at such extended time points.^[@R6],[@R28]^ Also, failure to go into spontaneous labor long beyond term may be related to pathological conditions, e.g. severe maternal obesity and certain congenital fetal malformations,^[@R5],[@R29]^ which impose methodological problems in the analysis.

Current evidence on routine induction is based on different approaches regarding what groups to compare. There seems to be three different ways of calculating, which presumably affect the results.

The "index week method"
-----------------------

Initially, most studies on routine induction past EDD used the "index week method". This method compares induction at 41+0--6 GW (intervention group) with pregnancies with spontaneous onset of labor at 41+0--6 GW (expectant group), i.e. the expectant group is defined by spontaneously initiated deliveries in the same week as the intervention group (Figure [1](#F1){ref-type="fig"}).
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Findings based on this method generally speak against induction at 41+0--6 GW and find induction associated with a higher risk of adverse outcomes.^[@R30]^ This is not surprising, because women with spontaneous onset of labor have better cervical status, which, in addition to spontaneous contractions, is a strong predictor for an uncomplicated delivery. Hence, by comparing with spontaneous labor in the same week only, this method neglects the risk of the ongoing pregnancy. However, the method has been criticized for being "unfair" and said not to reflect clinical daily life,^[@R6]^ because without induction, women will not necessarily go into spontaneous labor during the index week; these women may have a pre-labor cesarean section (CS) or an induction later in pregnancy.

The "next week method"
----------------------

As a response to the above discussion, Caughey *et al.*^[@R6]^ suggested another method. The "next week method" compares induction at 41+0--6 GW with all deliveries at 42+0 GW or later.^[@R30],[@R31]^ This approach was claimed to be more relevant, because defining the expectant group as all women who give birth after the index week ensures the risk of ongoing pregnancy to be taken into account. When this method is used, the expectant group includes any mode of labor onset (induced or spontaneous) as well as pre-labor CS, as long as the delivery takes place after the index week (Figure [2](#F2){ref-type="fig"}).
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Studies based on this method have generally not found induction at 41+0--6 GW associated with an increased risk of adverse outcomes,^[@R28],[@R30]^ and the findings have been used as an argument for routine induction at 41+0--6 GW. The method, however, has been criticized because it excludes a substantial number of spontaneous labor deliveries during the index week (41+0--6 GW) from the analysis, e.g. by Glantz *et al.* who have argued that spontaneous labor deliveries at 41+0--6 GW should be included in the expectant group.^[@R21]^

The "index+next week method"
----------------------------

The concerns illustrated above gave rise to a third approach, the "index+next week method", in which induction at 41+0--6 GW is compared with all non-induced deliveries during the index week and all deliveries during the following week (42+6 GW) (Figure [3](#F3){ref-type="fig"}). The expectant group may therefore go into spontaneous labor, have a pre-labor CS, or eventually end up with an induced delivery after the index week. This approach has been used in a few recent studies with inconclusive findings.^[@R21],[@R32]-[@R34]^
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The "index+next week method" ensures that the substantial number of women who go into spontaneous labor during the index week are accounted for, as well as risks related to the ongoing pregnancy. Despite these advantages, this approach is prone to an important bias source, because the pregnancy duration in the expectant group may exceed 42+6 GW. This introduces excessively increased risks for mother and child in the expectant groups, because the pregnancy can continue far beyond 42 GW. Expectant group definitions vary largely between studies that have used this approach,^[@R6],[@R28],[@R35],[@R36]^ which makes findings difficult to compare. Defining maximum pregnancy duration as 42+6 GW in the expectant group would reduce such bias.

The motivation for this review must be understood in the context of a generally increasing trend towards labor induction prior to post-term in low-risk pregnancies and the consequential need to clarify whether this shift in clinical practice implies negative consequences for mothers or babies. Objectives have been outlined in a previously published protocol.^[@R37]^ A search of PubMed, Cochrane, Web of Science, and *JBI Database of Systematic Reviews and Implementation Reports* did not identify any similar reviews or protocols.

Review question/objective
=========================

The objective of this review was to identify, assess and synthesize the best available evidence on the effects of induction prior to post-term on the mother and fetus. Maternal and fetal outcomes after routine labor induction in low-risk pregnancies at 41+0 to 41+6 GW (prior to post-term) were compared to routine labor induction at 42+0 to 42+6 GW (post-term).

Definitions
===========

For the purpose of this review, the following definitions will be used:

Estimated due date (EDD): Only studies with EDD determined by ultrasound were included. The ultrasound estimation must be from the first half of the pregnancy. Estimation of due date calculated by last menstrual period differs by an average of 5 days from EDD derived from early ultrasound examination.^[@R38]^ It is thus necessary to eliminate this possible source of bias by restricting to studies that estimate due date with the same method. More recent studies tend to use ultrasound estimated due date, therefore this method was chosen in the present review.

Low-risk pregnancy: A low-risk pregnancy is defined as one in which neither mother nor baby at the time of enrolment in the study are affected by conditions or circumstances that can complicate the delivery. Hence, in the present review this is defined as a singleton pregnancy with a fetus in vertex presentation and with no known risk factors or complications and a normally grown and formed baby.^[@R2]^

Elective induction: An induction performed for a nonmedical reason, e.g. a wish to schedule the delivery on a specific date or long transport to hospital. Also, some women request delivery because they are uncomfortable in the last weeks of pregnancy.^[@R39]^

Post-term: A pregnancy is post-term when it reaches two weeks past the EDD, i.e. 42+0 weeks (294 days) of gestation.^[@R5],[@R12]^

Prior to post-term: In this study, we define "prior to post-term" as a pregnancy length of 41+0 to 41+6 weeks (287--293 days) of gestation.^[@R12]^

Inclusion criteria
==================

Participants
------------

Participants included pregnant women at low risk of complications at the time of enrolment. To be included, both the fetus and the mother should be healthy, with no known risks besides the potential risk of the ongoing pregnancy. There should be intended vaginal birth with no contraindications, and EDD should be determined from ultrasound examination in order to obtain reasonably comparable measures of pregnancy length estimation.

Intervention
------------

The intervention of analysis was labor induction at 41+0--6 GW. Thus, the intervention group was composed of those who underwent labor induction at 41+0--6 GW. The expectant group was defined by all non-induced deliveries between 41+0 GW and 42+6 GW and all deliveries at 42+0--6 GW. This corresponds to the "index+next week method" described above with an additional restriction of the maximum pregnancy duration in the expectant group.

We included studies that used generally accepted induction methods: in cases of unfavorable cervix status, the induction agent could be prostaglandins (PGE1 or PGE2) or Foley catheter, while in cases of favorable cervix status, the induction method could be artificial rupture of membranes, oxytocin infusion, or artificial rupture of membranes followed by oxytocin infusion.^[@R40]^

Outcomes
--------

The perinatal and maternal outcomes examined in this review were selected based on their known or suggested association with prolonged pregnancy and/or induced delivery.

Perinatal outcomes (primary):

-   Low Apgar score (\< 7 after 5 minutes)

-   pH \< 7.10.

Perinatal outcomes (secondary):

-   Severe fetal complications (e.g. meconium aspiration, cerebral palsy, brachial plexus injury, hypoxic-ischemic encephalopathy)

-   Perinatal mortality

-   Hospitalization at neonatal intensive care unit

-   Pathological cardiotocography (CTG)

-   Shoulder dystocia

-   Infection.

Maternal outcomes (primary):

-   Cesarean section (CS)

-   Instrumental vaginal delivery.

Maternal outcomes (secondary):

-   Severe maternal complications (e.g. postpartum hemorrhage \> 1000 ml, uterine rupture, intensive care, sepsis, obstetric shock)

-   Maternal morbidity (e.g. chorioamnionitis)

-   Epidural anesthesia

-   Labor dystocia

-   Abnormal contractions (e.g. uterine tachysystole, hyperstimulation, precipitate labor)

-   Episiotomy or third or fourth degree lacerations

-   Length of hospital stay

-   Breastfeeding.

Measurement of outcomes varied between studies. Following an inclusive approach, the present meta-analysis included a varied range of outcomes. This approach resulted in the inclusion of one additional outcome, namely pH \< 7.10, which is now listed as a primary perinatal outcome together with low Apgar score, both being indicators of fetal distress. This is a deviation from the published protocol.^[@R37]^ Composite measures that varied between studies (e.g. neonatal morbidity score),^[@R33]^ were not considered comparable across studies and, thus, not included. Finally, data allowed for analyses of sub-measures of the overall primary maternal outcome: CS (including CS due to failure of progress, CS due to fetal distress, and CS after previous vaginal birth).

Types of studies
----------------

We included randomized controlled trials (RCTs), quasi-experimental trials, and cohort studies. Cohort studies were included because large-scale studies are needed when investigating rare outcomes, such as mortality and low Apgar scores. Randomized and quasi-experimental studies were analyzed together and separate from cohort studies.

Methods
=======

Search strategy
---------------

A three-step search strategy was used in order to identify publications from peer-reviewed journals as well as gray literature. The initial search terms were decided through discussions between authors and a research librarian to ensure identification of the maximum number of relevant articles.

An initial search limited to PubMed and CINAHL was undertaken and followed by an analysis of the text words contained in titles and abstracts and of the index terms used to describe the articles. All identified keywords and index terms were used in a second search performed across all included databases (please see below). The second search revealed keywords and terms from index text, which lead to further exploration, where terms such as a different spelling of cesarian and labor were added. Thirdly, the reference lists from each identified publication were searched for additional studies. The search was conducted Jan 2014--June 2018. Individual search strategies are presented in Appendix I.

Studies published in English, Danish, Swedish and Norwegian were considered for inclusion, and authors of primary studies were contacted in cases of missing information or to clarify unclear data.

According to rapid changes in fetal surveillance management, labor induction routines, and methods for estimating due date, studies were restricted to publications within the last two decades (1998--2018).

Databases included PubMed, CINAHL, Embase, Scopus, Swemed+, POPLINE, Cochrane, TRIP, Current Controlled Trials, and Web of Science.

Additional searches for published literature included hand searching of reference lists and bibliographies of included articles.

Search for gray literature included MedNar, Google Scholar, OpenGrey, ProQuest Nursing and Allied Health Source, and guidelines from the National Institute for Health and Care Excellence, the WHO, the Royal College of Obstetricians and Gynaecologists, the American College of Obstetricians and Gynecologists, and the Society of Obstetricians and Gynaecologists of Canada.

Assessment of methodological quality
------------------------------------

For methodological validity prior to inclusion of studies, papers selected for retrieval were reviewed by all three authors independently using the 2014 edition of a standardized critical appraisal instrument from the JBI SUMARI.^[@R41]^ Please find the exact wording of the appraisal instrument questions in the Results section (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Any disagreements between the authors were resolved through discussion. When information was unclear, we attempted to contact the authors of the assessed studies for clarification.

###### 

Assessment of methodological quality of randomized controlled and quasi-randomized trials

  Citation                             Q1   Q2   Q3   Q4   Q5   Q6    Q7   Q8    Q9    Q10
  ------------------------------------ ---- ---- ---- ---- ---- ----- ---- ----- ----- -----
  Burgos *et al.* (2012)^[@R43]^       Y    N    Y    NA   N    Y     U    Y     Y     Y
  Daskalakis *et al.* (2013)^[@R13]^   N    N    N    NA   N    Y     Y    Y     Y     Y
  Gelisen *et al.* (2005)^[@R34]^      Y    N    Y    Y    N    Y     N    Y     Y     Y
  Heimstad *et al.* (2007)^[@R33]^     Y    N    Y    Y    N    Y     Y    Y     Y     Y
  Total (%)                            75   0    75   50   0    100   50   100   100   100

Y, yes; N, no; NA, not applicable; U, unclear.

Q1: Was the assignment to treatment groups truly random? Q2: Were participants blinded to treatment allocation? Q3: Was allocation to treatment groups concealed from the allocator? Q4: Were the outcomes of people who withdrew described and included in the analysis? Q5: Were those assessing outcomes blind to the treatment allocation? Q6: Were the control and treatment groups comparable at entry? Q7: Were groups treated identically other than for the named interventions? Q8: Were outcomes measured in the same way for all groups? Q9: Were outcomes measured in a reliable way? Q10: Was appropriate statistical analysis used?.

Burgos *et al.* 2012: Unclear description of statistical analysis of continuous data, but it appears from the presentation of data that appropriate statistical tests have been used.

Daskalakis *et al.* 2013: Unclear description of risk status of participants, but when contacted, author confirmed that the study group did not have any medical complications.

Gelisen *et al.* 2005: Unclear description on withdrawals, but it appears from the presentation that all participants stayed in the study.

Heimstad *et al.* 2007: Unclear description of the definition of low-risk of the mother, but, even though we did not achieve contact with the authors, the randomization should ensure equal distribution of potential medical conditions.

###### 

Assessment of methodological quality of cohort studies

  Citation                            Q1    Q2   Q3   Q4   Q5    Q6    Q7   Q8    Q9
  ----------------------------------- ----- ---- ---- ---- ----- ----- ---- ----- -----
  Cheng *et al.* (2012)^[@R45]^       Y     U    U    Y    Y     Y     NA   Y     Y
  Jacquemyn *et al.* (2012)^[@R44]^   Y     Y    Y    U    Y     Y     NA   Y     Y
  Liu *et al.* (2013)^[@R46]^         Y     Y    Y    Y    Y     Y     NA   Y     Y
  Total (%)                           100   67   67   67   100   100   0    100   100

Y, yes; N, no; NA, not applicable; U, unclear.

Q1: Is sample representative of patients in the population as a whole? Q2: Are the patients at a similar point in the course of their condition/illness? Q3: Has bias been minimized in relation to selection of cases and of controls? Q4: Are confounding factors identified and strategies to deal with them stated? Q5: Are outcome assessed using objective criteria? Q6: Was follow up carried out over a sufficient time period? Q7: Were the outcomes of people who withdrew described and included in the analysis? Q8: Were outcomes measured in a reliable way? Q9: Was appropriate statistical analysis used?

Cheng *et al.* 2012: Unclear description of risk status between groups. Data suggest that enrolment and risk status was only performed once at enrolment in 39 +0 GW for the expectant arm. No response from authors, when contacted for confirmation.

Jacquemyn *et al.* 2012: Unclear description of calculation of EDD. Author confirmed that ultrasound had been the standard method for determining EDD.

Liu *et al.* 2013: Unclear description of the risk status of participants. Author confirmed that the included women were low-risk at inclusion.

We included all studies that fulfilled the inclusion criteria and that the authors considered of acceptable methodological quality, according to the critical appraisal tool from JBI SUMARI.^[@R41]^

Data extraction
---------------

Data were extracted from the included papers using the standardized JBI data extraction tool.^[@R41]^ Studies selected for retrieval are presented in Appendices II-IV. Appendix II presents general characteristics on included studies. Appendix III presents details on methods for estimation of due date, comparison groups, parity, and induction agents in included studies. Appendix IV presents an overview of outcome measures in included studies. Reasons for exclusion for screened, excluded studies are shown in Appendix V.

Data synthesis
==============

Data from the included studies were pooled in a statistical meta-analysis model using RevMan 5 (Copenhagen: The Nordic Cochrane Centre, Cochrane). To minimize errors all pooled statistics were subject to double data entry. Effect sizes expressed as risk ratios (for categorical data) and weighted mean differences (for continuous data) and corresponding 95% confidence intervals (CI) were calculated. Statistical heterogeneity was assessed in the meta-analysis using the I^2^ and chi-squared statistics, and heterogeneity was considered substantial if I^2^ \>50% and P value \< 0.10 in the chi-square test for heterogeneity.^[@R42]^ Subgroup-analysis according to type of study design were performed. Where statistical pooling was not possible the findings have been presented in narrative form, and with tables and figures where appropriate to facilitate interpretation.

Results
=======

Study inclusion
---------------

Figure [4](#F4){ref-type="fig"} shows the results of our search strategy, where 4212 records were identified in the first step. Of these 3442 were identified through database search and 770 from other sources. After abstract reading 33 studies remained for full text-reading, which further excluded 25 studies (Appendix V). We assessed eight full text papers for eligibility and excluded one due to inconsistent methods for due date estimation (i.e. many of the participants in the study had calculation by last menstrual period as the only calculation method). The remaining seven studies were selected for retrieval (Appendix II).
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Seven studies were included: two randomized trials^[@R33],[@R34]^ and two quasi-experimental trials^[@R13],[@R43]^ with a total of 5119 participants,^[@R13],[@R33],[@R34],[@R43]^ and three cohort studies with 356,338 participants.^[@R44]-[@R46]^

Methodological quality
----------------------

### Assessment of risk of bias in randomized and quasi-experimental studies

Table [1](#T1){ref-type="table"} shows the scoring of the included randomized trials and quasi-experimental studies according to the JBI SUMARI critical appraisal tools for RCTs/quasi-experimental studies.^[@R41]^

#### Comparability at entry (selection bias, confounding) (Q1, Q3, Q6)

Randomization (Q1) and concealment of allocation to allocator (Q3) are important factors in the evaluation of whether the intervention and control groups were comparable at baseline. In two studies,^[@R33],[@R34]^ randomization was conducted via computer or use of opaque sealed envelopes and, thus, scored as truly randomized and with allocation concealed from the allocator. In another study,^[@R43]^ allocation was determined by calendar period meaning that no clinician or researcher could affect allocation to treatment group in the clinical setting. Hence, this study was also considered to have truly random allocation. The Daskalakis study allocation was considered not truly random, as allocation was determined according to the attending physician\'s preference, and no information was presented as to how the participants were assigned a given physician.^[@R13]^ Question 6 serves to corroborate the randomization in the studies, i.e. only when baseline characteristics turn out to be similar in the two groups is confounding truly minimized, as compared to observational studies. For all four studies, we considered treatment and comparison groups to be comparable at entry. Even though the Daskalakis study only presented a few baseline characteristics (age, parity and ethnicity), the groups were considered comparable, because no statistically significant differences were seen for the examined characteristics.

#### Blinding (Q2, Q5)

Blinding is used in trials to enhance group comparability and minimize confounding. When the intervention under study is labor induction, concealment of treatment group to participants is not possible. Hence, all included trials were assigned a "no" in Q2, meaning that in none of the studies the participants were blinded to treatment allocation. In the two quasi-experimental studies, the studies were planned and data extracted retrospectively.^[@R13],[@R43]^ Hence, by the time of data collection, neither participants nor clinicians were aware that a comparison would be made between induction and expectant management, and, thus, were not affected by a knowledge of an ongoing trial in the assessment of outcomes. Even so, in the clinical situation the assessment and registration of outcomes for a participant is likely affected by the individual clinician\'s knowledge on induction vs. expectant management. This poses a risk of bias on the part of clinicians. For the included outcomes, however, we considered lack of blinding by the time of data collection of limited importance due to the character of the outcomes. Concealment of treatment group by the time of analysis is also difficult for labor induction. One study, however, blinded the researcher to some extent by blinding information on tachycardia and hyperstimulation in order to prevent the effects of researcher knowledge of treatment when evaluating outcomes.^[@R34]^

#### Loss to follow-up and treatment differences (selection bias) (Q4, Q7)

Question 4 addresses selection bias due to loss of follow-up and concerns information on outcome for participants who withdrew from the study. By design, the two quasi-experimental trials could not have any withdrawals and were therefore assigned "not applicable" in Q4. The two RCTs fulfilled this criterion. Question 7 addresses treatment differences between groups other than the intervention of interest, which may induce selection bias. In two studies we considered treatment of participants to be similar in the compared groups.^[@R13],[@R33]^ In one study it was unclear whether groups were treated identically, since deliveries took place during different calendar periods, and no information was given as to any other potential changes in procedures between the two periods.^[@R46]^ The total study period, however, was no longer than three years, and the intervention period followed the control period immediately, indicating a limited risk of important time-dependent bias. In one study, the design allowed for systematic differences in induction methods between groups^[@R34]^ and, thus, we considered groups not to be properly comparable. In this study, the intervention group included deliveries induced by misoprostol medical treatment, oxytocin medical treatment, or Foley-catheter, while those in the expectant group, who had not gone into spontaneous labor at 41+0--6 GW and were induced at 42+0--6 GW, were all treated with misoprostol as induction agent.

#### Outcome assessment (Q8, Q9)

Questions 8 and 9 relate to differences in outcome measurement between groups and reliability in the measurements. For all four randomized trials, we considered outcomes as measured in the same reliable way, including the use of international standardized measures (e.g. CS, Apgar score). In one study, the authors had generated a composite outcome of neonatal morbidity^[@R33]^ that did not rely on solid empirical basis, which may impose some degree of uncertainty about this measure.

#### Statistical analysis (Q10)

All studies presented intention-to-treat analyses, which is considered a relevant method in RCTs. In one study additional sensitivity analyses were performed.^[@R33]^ The same study also presented analyses with imputation of missing data (e.g. on pH-values in the newborn). The three other studies did not explain how they handled missing data.

### Assessment of risk of bias in cohort studies

Table [2](#T2){ref-type="table"} shows the scoring of the included cohort studies according to the JBI SUMARI critical appraisal tools for cohort studies.^[@R41]^

#### Generalizability (Q1)

Question 1 concerns generalizability of included cohort studies. For all three studies, we considered study populations to be representative of the background population.

#### Comparability at entry (selection bias, confounding) (Q2, Q3, Q4)

Question 2 concerns possible differences between groups at study entry. For two studies, we considered groups to be comparable at the time of inclusion.^[@R44],[@R46]^ In one study, it was not clear whether participants in the expectant group were at a poorer health status at 41+0--6 GW than the intervention group, because risk status was assessed at 39+0 GW.^[@R45]^ Authors were approached, but we did not achieve contact. The degree of possible bias was therefore not able to be assessed. Question 3 concerns allocation into the intervention and expectant groups. For all three studies, we found that bias had been minimized with regard to allocation to the two groups. Question 4 asks about proper identification and handling of confounding factors. In two studies we regarded this to be appropriate,^[@R44],[@R46]^ whereas the third study lacked important confounding variables, such as smoking and BMI.^[@R45]^

#### Follow-up period (Q6)

All studies had follow-up periods long enough to evaluate the outcomes of interest.

#### Loss to follow-up (Q7)

As was the case for the randomized and quasi-experimental studies, due to the design of the studies and the character of the intervention under study, no participants withdrew, and, thus, all studies were assigned "not applicable" in Question 7.

#### Outcome measurement (comparability, measurement error) (Q5, Q8)

The questions 5 and 8 regard measurement of outcome. This review includes several different outcomes, and we estimated that the vast majority of these followed objective criteria and were measured in a reliable way in all three studies. One study lacked precise definitions on outcomes, such as birth injury, chorioamnionitis, and labor dystocia,^[@R45]^ but we did not consider this an important limitation to the results.

#### Statistical analysis (Q9)

We considered all studies to have used appropriate statistical methods for analysis. One study, though, did not perform adjustment for confounders, because such information was not available.^[@R44]^ Even though confounder adjustment is a desirable tool in cohort analyses, we concluded that the authors had used proper statistical tools, given the available data. It should be noted, that none of the three cohort studies presented information on the presence or handling of missing data. It is therefore not possible to evaluate possible biases related to missing information.

Overall, the included studies had fair methodological quality according to their respective study design. None of the experimental studies performed blinding of participants or clinicians to treatment allocation, but since this is not possible for induction of labor, we do not consider this a serious bias source. Generally, we considered treatment groups comparable at entry, though one quasi-randomized and one cohort study might be prone to selection bias. Further, we considered outcomes to be measured appropriately, data analyzed by appropriate methods, follow-up periods to be adequate, and for cohort studies, the study populations were reasonably representative of the background population.

Review findings
===============

Perinatal and maternal outcomes are presented and evaluated according to induction vs. expectant management, as follows.

Perinatal outcomes
------------------

Table [3](#T3){ref-type="table"} gives an overview of all pooled risk estimates for perinatal outcomes. Individual meta-analyses are presented in Appendix VI.

###### 

Perinatal outcomes according to routine labor induction at 41+0--6 vs. 42+0--6 gestational weeks

  Outcome                                     Study design   Number of studies   Number of participants   Risk measure          Effect size, 95% CI
  ------------------------------------------- -------------- ------------------- ------------------------ --------------------- ---------------------
  *Perinatal outcomes (primary)*                                                                                                
  Apgar score \< 7 after 5 min.               Cohort         1                   74,952                   RR                    0.90 \[0.79, 1.03\]
  RCT                                         3              4671                RR                       0.90 \[0.52, 1.56\]   
  pH \< 7.10                                  RCT            2                   4071                     RR                    1.90 \[1.48, 2.43\]
  *Perinatal outcomes (secondary)*                                                                                              
  Admission to neonatal intensive care unit   Cohort         1                   26,364                   RR                    0.94 \[0.83, 1.07\]
  RCT                                         3              4671                RR                       1.08 \[0.68, 1.71\]   
  Macrosomia (birth weight \> 4500g)          RCT            2                   4163                     RR                    0.76 \[0.56, 1.05\]
  Meconium aspiration syndrome                Cohort         1                   48,518                   RR                    0.77 \[0.57, 1.05\]
  RCT                                         2              1108                RR                       0.65 \[0.31, 1.37\]   
  Meconium stained amniotic fluid             RCT            3                   4671                     RR                    0.82 \[0.75, 0.91\]
  Oligohydramnios                             RCT            1                   508                      RR                    0.40 \[0.24, 0.67\]
  Perinatal death                             RCT            4                   5099                     RR                    0.22 \[0.04, 1.32\]
  Resuscitation                               RCT            1                   508                      RR                    1.50 \[0.62, 3.61\]
  Shoulder dystocia                           RCT            2                   1038                     RR                    0.28 \[0.08, 1.00\]
  Ventilation \> 6 hours                      Cohort         1                   26,364                   RR                    1.36 \[0.95, 1.93\]

CI, confidence interval; MD, mean difference; RCT, randomized controlled trial; RR, relative risk.

### Perinatal outcomes (primary)

Routine induction at 41+0--6 GW was associated with an almost doubled risk of low pH (\< 7.10) compared to expectant management on pooled data from two RCTs (relative risk \[RR\] 1.90, 95% CI 1.48, 2.43). No association was observed for low Apgar score (\< 7 after 5 minutes).

### Perinatal outcomes (secondary)

The analysis showed a reduced risk in the induction group of oligohydramnios (RR~RCT~ 0.40, 95% CI 0.24, 0.67), meconium stained amniotic fluid (RR~RCT~ 0.82, 95% CI 0.75, 0.91), and shoulder dystocia (RR~RCT~ 0.28, 95% CI 0.08, 1.00) compared to the expectant group. The latter, however, with substantially broad CI. The analysis on meconium stained amniotic fluid was compromised by substantial heterogeneity.

Perinatal death was not associated with either labor induction or expectant management; data showed a relative risk of 0.22 (95% CI 0.04, 1.32) in the intervention group compared to expectant management based on pooled data from four RCTs. This corresponds to an absolute risk reduction in perinatal death of 0.002 for routine induction at 41+0--6 GW compared to 42+0--6 GW. In other words, one prevented perinatal death per 501 inductions (95% CI 247 to 18,439) or two saved lives per 1000 inductions. Since perinatal deaths are rare, and results based on small numbers may cause important changes in clinical procedures, each perinatal death event should be described and choices on whether to include each of the events in final analysis explained. In this review, it was a criterion for inclusion of participants, that both fetus and mother were healthy and with no known risks at inclusion. This means that perinatal death events that were not related to either induction or expectant management were not included in the analysis. In the following, each perinatal death event in the included primary studies is evaluated: in the Heimstad study, one neonatal death was reported in the expectant group.^[@R33]^ This fatal event occurred during labor after normal cardiotocogram at admission, and cause of death was explained by a true umbilical cord knot. This event was not included in the meta-analysis, because the death reason is not likely to be related to the intervention. Including the event did not change any conclusions (data not shown). In the Gelisen study, one intrauterine death was reported in the expectant group, but no explanation of the cause of death was given.^[@R34]^ The authors were contacted for clarification, but no response was obtained. Despite the lack of explanation, this event was included in the meta-analysis in order to present "worst case scenario". Finally, the Burgos study comprised three perinatal deaths in the intervention group and seven in the expectant group.^[@R43]^ Four (two in each group) out of the fatal events within the first 28 days after birth were explained by severe congenital malformations. These four events were not included in the present meta-analysis. In the intervention group, we included one pre-labor intrauterine death, and in the expectant management group, we included four prenatal deaths and one neonatal death within the first 24 hours after birth from the Burgos study. From this, follows that the Burgos study contributed with 62% of the data in the meta-analysis and with six of the eight perinatal deaths included. It is unclear whether a relatively high mean age (32.8 years) and proportion of nulliparous women (63--64%) in the study could contribute to the relatively high incidence of perinatal death in the expectant arm compared to other studies on the topic.^[@R24],[@R36]^ We contacted the authors for further details, who confirmed, that the expectant management group had antenatal control with CTG and amniotic fluid at 41+3/4 GW.

Maternal outcomes
-----------------

Table [4](#T4){ref-type="table"} gives an overview of all pooled risk estimates for maternal outcomes.

###### 

Maternal outcomes according to routine labor induction at 41+0--6 vs. 42+0--6 gestational weeks

  Outcome                                           Study design   Number of studies   Number of participants   Risk measure          Effect size, 95% CI
  ------------------------------------------------- -------------- ------------------- ------------------------ --------------------- ----------------------
  *Maternal outcomes (primary)*                                                                                                       
  Cesarean section (overall)                        Cohort         1                   74,860                   RR                    1.11 \[1.09, 1.14\]
  RCT                                               4              5109                RR                       1.11 \[0.98, 1.26\]   
  Cesarean section (failure to progress)            RCT            2                   1038                     RR                    1.43 \[1.01, 2.03\]
  Cesarean section (fetal distress)                 RCT            2                   1038                     RR                    1.06 \[0.75, 1.48\]
  Cesarean section (after previous vaginal birth)   Cohort         1                   3156                     RR                    1.56 \[1.05, 2.34
  Instrumental vaginal delivery                     Cohort         1                   49,628                   RR                    1.30 \[1.24, 1.36\]
  RCT                                               3              4509                RR                       1.00 \[0.90, 1.11\]   
  Vaginal delivery                                  RCT            3                   4601                     RR                    0.97 \[0.93, 1.02\]
  *Maternal outcomes (secondary)*                                                                                                     
  Chorioamnionitis                                  Cohort         1                   75,218                   RR                    1.13 \[1.05, 1.21\]
  Epidural                                          RCT            1                   438                      RR                    0.95 \[0.76, 1.19\]
  Hospital stay (days)                              RCT            1                   438                      MD                    0.10 \[-0.04, 0.24\]
  Hyperstimulation                                  RCT            1                   600                      RR                    1.00 \[0.29, 3.42\]
  Labor dystocia                                    Cohort         1                   51,473                   RR                    1.29 \[1.22, 1.37\]
  RCT                                               1              508                 RR                       0.55 \[0.20, 1.45\]   
  Manual removal of placenta                        RCT            1                   438                      RR                    1.08 \[0.44, 2.66\]
  Maternal intensive care                           Cohort         1                   277,964                  RR                    1.59 \[0.96, 2.62\]
  Obstetric shock                                   Cohort         1                   277,964                  RR                    0.89 \[0.38, 2.12\]
  Precipitate labor                                 RCT            1                   508                      RR                    2.75 \[1.45, 5.20\]
  Postpartum hemorrhage (blood transfusion)         Cohort         1                   277,964                  RR                    1.04 \[0.92, 1.17\]
  Postpartum hemorrhage \> 500 ml                   RCT            1                   508                      RR                    0.91 \[0.57, 1.45\]
  Postpartum hemorrhage \> 1000ml                   RCT            1                   438                      RR                    1.43 \[0.62, 3.33\]
  Postpartum sepsis                                 Cohort         1                   277,964                  RR                    0.92 \[0.71, 1.17\]
  Severe perineal lacerations                       RCT            1                   508                      RR                    1.20 \[0.62, 2.33\]
  Tachysystole                                      RCT            1                   600                      RR                    1.29 \[0.49, 3.41\]
  Thromboembolism                                   Cohort         1                   277,964                  RR                    1.49 \[0.59, 3.77\]
  Uterine rupture                                   Cohort         1                   277,964                  RR                    1.97 \[1.54, 2.52\]

CI, confidence interval; MD, mean difference; RCT, randomized controlled trial; RR, relative risk.

### Maternal outcomes (primary)

All relative risks for different measures of CS were above 1.00 indicating an increased risk in the intervention group compared to expectant management. Statistical significance was found for overall CS (RR~cohort~ 1.11 95% CI 1.09, 1.14) (one study, n = 74,860), CS due to failure to progress (RR~RCT~ 1.43, 95% CI 1.01, 2.03) (two studies, n = 1038), and CS after previous vaginal birth (RR~cohort~ 1.56, 95% CI 1.05, 2.34) (one study, n = 3165). The RCT-analysis on overall CS showed the same relative risk as the statistically significant cohort-analysis, but the estimate was just non-statistically significant. The analysis on CS due to failure to progress was compromised by substantial heterogeneity. Routine induction at 41+0--6 GW was associated with a 30% increased risk of instrumental vaginal delivery (RR~cohort~ 1.30, 95% CI 1.24, 1.36) (one study, n = 49,628), while pooled data from three RCTs did not show any association.

### Maternal outcomes (secondary)

For secondary maternal outcomes, all analyses except vaginal delivery were based on only one of the included studies. We found routine induction at 41+0--6 GW associated with an increased risk of chorioamnionitis (RR~cohort~ 1.13, 95% CI 1.05, 1.21) (one study, n = 75,218), labor dystocia (RR~cohort~ 1.29, 95% CI 1.22, 1.37) (one study, n = 51,473), precipitate labor (RR~RCT~ 2.75, 95% CI 1.45, 5.20) (one study, n = 508), and uterine rupture (RR~cohort~ 1.97, 95% CI 1.54, 2.52) (one study, n = 277,964). The RCT-analysis on labor dystocia suffered from substantial lack of statistical power and could not support any conclusions. None of the other outcomes were associated with the intervention, except for a borderline non-significantly elevated risk of maternal intensive care (RR~cohort~ 1.59, 95% CI 0.96, 2.62) (one study, n = 277,964).

Additional findings: spontaneous onset of labor
-----------------------------------------------

Spontaneous onset of labor is a central element in the discussion on how to determine preferable timing of labor induction after due date. Even so, spontaneous onset of labor could not be examined in this review, because, by design, the intervention group will have close to zero spontaneous onsets of labor, and comparison with the expectant group would not make sense. Three studies, however, presented statistics on spontaneous onset of labor in the expectant group.^[@R13],[@R33],[@R43]^ In the RCT by Heimstad, participants were randomized to immediate induction at 41+2 GW (n = 254) or to expectant management up to 42+6 GW (n = 254).^[@R33]^ In the expectant group, 176 went into spontaneous labor (69%), 59 were induced due to medical reasons (most often oligohydramnios), while the remaining 19 women were still pregnant by 42+6 GW and had their labor induced. In the Daskalakis study, participants were selected for induction of labor at 41+1 GW (n = 211) or expectant management until 42+1 GW (n = 227) depending on the attending physician\'s preference.^[@R13]^ In the expectant group, 168 went into spontaneous onset of labor (74%), 31 were induced due to medical reasons, and 28 were still pregnant, and induced, by 42+1 GW. Finally, the quasi-experimental trial by Burgos found that with a policy of inducing at 42+0 GW, 71% had spontaneous onset of labor.^[@R43]^ This is in line with the pooled statistics from all three studies, where a total of 1584 out of 2227 women (71.4%), who followed expectant management, went into spontaneous labor during the expectant time window.^[@R13],[@R33],[@R43]^ Also, the two quasi-experimental studies^[@R13],[@R43]^ experienced a 20% increase in inductions when using a guideline of recommending induction 41+0--6 GW.

Communicating benefits and harms
--------------------------------

Risk differences have been shown to seem greater when presented in relative terms compared to absolute numbers.^[@R47],[@R48]^ Researchers and clinicians need to be aware of this when communication scientific evidence to patients or policy makers. In order to make significant results more comprehensible Table [5](#T5){ref-type="table"} shows absolute risks (AR) and numbers needed to treat (NNT) for all outcomes with statistically significant results in Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}, and where estimates from observational and experimental analyses pointed in the same direction.

###### 

Absolute numbers for perinatal and maternal outcomes according to routine labor induction at 41+0--6 vs. 42+0--6 gestational weeks

  Outcome                                                         Study design (no.)   Absolute numbers (per 1000 inductions)   NNT (95% CI)                                     ARR     ARI
  --------------------------------------------------------------- -------------------- ---------------------------------------- ------------------------------------------------ ------- -------
  *Perinatal outcomes*                                                                                                                                                                   
  Meconium stained amniotic fluid                                 RCT (n = 3)          50 fewer events                          1 event prevented by 20 induced \[13, 41\]       4.9%    
  Oligohydramnios                                                 RCT (n = 1)          100 fewer events                         1 event prevented by 10 induced \[6, 20\]        10.6%   
  pH \< 7.10                                                      RCT (n = 2)          40 extra events                          1 adverse event by 25 induced \[18, 41\]                 4%
  *Maternal outcomes*                                                                                                                                                                    
  Cesarean section (overall)[^†^](#TF23-1){ref-type="table-fn"}   Cohort (n = 1)       36 extra events                          1 adverse event by 28 induced \[23, 33\]                 3.7%
  Cesarean section (failure to progress)                          RCT (n = 2)          33 extra events                          1 adverse event by 30 induced \[0, 7\]                   3.4%
  Cesarean section (after previous vaginal birth)                 Cohort (n = 1)       13 extra events                          1 adverse event by 75 induced \[39, 808\]                1.3%
  Chorioamnionitis                                                Cohort (n = 1)       5 extra events                           1 adverse event by 195 induced \[123, 460\]              0.5%
  Labor dystocia[^‡^](#TF23-2){ref-type="table-fn"}               Cohort (n = 1)       22 extra events                          1 adverse event by 45 induced \[36, 59\]                 2.2%
  Precipitate labor                                               RCT (n = 1)          77 extra events                          1 adverse event by 13 induced \[8, 30\]                  8.3%
  Uterine rupture                                                 Cohort (n = 1)       0.7 extra events                         1 adverse event by 1522 induced \[1124, 2757\]           0.07%

ARI, absolute risk increase; ARR, absolute risk reduction; CI, confidence interval; NNT, number needed to treat; RCT, randomized controlled trial.

^†^One cohort study was not accounted for in this calculation, as it only included multipara with at least one normal birth. An inclusion would have diluted the results regarding all women.

^‡^One minor inconclusive RCT with few events was ignored.

Absolute risk reduction (ARR) and absolute risk increase (ARI) are measures of the strength of the association, where the baseline risk in the induction and the expectant groups have been taken into account. For example, low pH will often be presented as RR = 1.90 or as a 90% increased risk after induction at 41+0--6 GW compared to expectant management. Since relative risks do not take into account the prevalence of low pH, it may be difficult for patients and stakeholders to consider the size of the problem. Using absolute numbers brings this aspect into the information given. In the case of low pH, the information could be that for every 1000 induced deliveries, 40 extra children would be born with a low pH compared to expectant management. Or, for every 25 induced deliveries, one extra child will be born with a low pH (with a 95% certainty between 18 and 41), and the last way to explain it is, that labor induction increases the number of children with low pH by 4%.

Discussion
==========

The aim of this systematic review was to evaluate the effects of induction of labor prior to post-term in low-risk pregnancies. Routine induction at 41+0--6 GW has become a widespread obstetric practice in many Western countries despite a lack of systematic reviews that address both harms and benefits of the intervention. Acknowledging the fact that our analyses are based on a limited number of primary studies, this review qualifies current knowledge and depicts critical methodological aspects in existing research in the field. In the following, we present main findings, discuss the quality of included studies, and describe important methodological problems in systematic reviews on labor induction. Implications for practice from changed guidelines and derived organizational/economic consequences are also touched upon, as well as the communication of systematic review results to patients.

In summary, we found induction at 41+0--6 GW associated with a few beneficial outcomes (e.g. a reduced risk of oligohydramnios and meconium stained amniotic fluid) and several adverse outcomes (e.g. an increased risk of precipitate labor, labor dystocia, CS, uterine rupture, chorioamnionitis and low pH in the newborn) compared to expectant management. As emphasized by the WHO, expected benefits from a medical intervention must outweigh potential harms.^[@R3]^

Overall, previous systematic reviews have found induction associated with a reduced risk of CS, perinatal death, meconium stained amniotic fluid and perhaps meconium aspiration syndrome with induction prior to post-term.^[@R6],[@R35],[@R36]^ Our results largely support previous findings on perinatal outcomes, except for perinatal death and aspiration syndrome. In regard to maternal outcomes, our findings generally do not support those of previous reviews, i.e. we found an increased risk of CS and several adverse outcomes.

Regarding perinatal outcomes, our findings are aligned with a systematic review by Caughey *et al.*^[@R6]^ finding that evidence was insufficient to form conclusions for many of the key neonatal outcomes (e.g. neonatal death, fetal distress and asphyxia). As for perinatal death, our data indicated two possibly prevented fetal deaths per 1000 inductions with routine induction at 41+0--6 GW. However, conclusions could not be drawn due to lack of statistical power illustrated by a very broad CI in relative numbers (RR 0.22, 95% CI 0.04, 1.32) and, in absolute numbers, a range of 247 to 18,439 inductions to be performed to prevent one perinatal death. A Cochrane meta-analysis on induction of labor at or beyond term^[@R35]^ found that a policy of labor induction was associated with fewer (all-cause) perinatal deaths (RR 0.31, 95% CI 0.12, 0.88), and Wennerholm *et al.*^[@R36]^ found a decreased risk of perinatal death (RR 0.33, 95% CI 0.10, 1.09), even though it was not statistically significant. In the Wennerholm study, only pregnancies beyond term were included, which makes this review more comparable to ours. Wennerholm *et al.*^[@R36]^ found meconium aspiration syndrome to be reduced (RR 0.43, 95% CI 0.23, 0.79), and Caughey *et al.* and Gulmezoglu *et al.* found similar conclusions.^[@R6],[@R35]^ Our data showed a decreased risk of meconium stained amniotic fluid, but we found no association with meconium aspiration syndrome. Further, we found an increased risk of pH \< 7.10 in the newborn, which can be a serious acute condition and is associated with long-term consequences, such as cerebral palsy. On the other hand, we did not find low Apgar score associated with induction prior to post-term.

Regarding maternal outcomes, Wennerholm *et al.*^[@R36]^ found a 13% decreased risk of CS after induction (RR 0.87, 95% CI 0.80--0.96), and the findings are supported by a Cochrane review^[@R35]^ and Caughey *et al.*^[@R6]^ In the present review, we found an 11% increased risk of CS. We believe this is due to differences in methodology, which will be discussed below. The pooled RR for CS was statistically significant in the cohort analysis, but not in the analysis including four RCTs. The largest RCT, however, by Burgos^[@R43]^ which weighs 54%, found a significant increase in CS, which supports the conclusions from our cohort analysis. Cesarean section has been associated with an increased risk of excessive bleeding, pain, bladder disorders, hysterectomy, and neonatal death, and, in subsequent pregnancies, placenta previa, fetal death and uterine rupture.^[@R49]-[@R51]^ Finally, we found chorioamnionitis, labor dystocia, precipitate labor and uterine rupture associated with induction prior to post-term. Uterine rupture is a rare, but potentially life-threatening condition, and it imposes severe risks in subsequent pregnancies.^[@R52]^ Unfortunately, even though several adverse birth outcomes are associated with long-term risks, we were not able to evaluate such effects, since none of the primary studies included long-term outcomes.

Overall, the methodological quality of the included studies was considered high when assessed according to the JBI SUMARI critical appraisal tools for RCTs/quasi-experimental studies and observational studies, respectively. This was expected, because one of the main purposes of this review was to restrict data to updated studies. Generalizability and length of follow-up period (both relevant only for cohort studies), measurement and assessment of outcome and statistical analysis were the items best covered in the included studies. Comparability of groups at entry was not satisfactory in two out of seven studies. For example, in one quasi-experimental trial, assignment to treatment groups was determined according to the attending physician\'s preference. Selection bias due to loss of follow-up was minimal in the two RCTs that this criterion applied to, whereas one of the two RCTs was prone to selection bias due to treatment differences, because induction agents differed between groups.

The question(s) addressed in systematic reviews are said often to be (too) simple and (too) general, e.g. a title like "Elective Induction of Labor Versus Expectant Management of Pregnancy"^[@R6]^ may include all varieties of women, a broad variation in gestational age, different induction agents etc. This is the reason why careful attention should be paid to inclusion criteria, when systematic reviews are interpreted. Systematic reviews form the main evidence base for clinical guidelines today, and it is crucial that policy makers and stakeholders pay careful attention to the criteria for inclusion of studies, because inclusion criteria are central for a review\'s external validity and relevance.^[@R53]^

Regarding gestational age criteria, even though our literature search resulted in a large amount of papers on induction of labor versus expectant management, only a few studies compared the relatively tight timeframes of 41+0--6 GW and 42+0--6 GW, which reflects the new routine versus the old standard in many Western countries. Tight timeframes for comparison of the groups were chosen in the present review, because they reflect this change in practice. In the Cochrane review, only three of 22 randomized studies met this criterion, while the remaining 19 studies included variations from 37 GW up to expectant management with no upper time limit.^[@R35]^ In the present study, we only identified four RCTs or quasi-randomized trials (n = 5109) and three cohort studies (n = 356,338), that met our criteria regarding gestational age. We argue that meta-analyses that use broad criteria for gestational age in the expectant group are likely to overestimate poor fetal or maternal outcomes from expectant management. The main reason for this is that the expectant group includes excessively long pregnancies with correspondingly increased complication risk.^[@R6],[@R35],[@R36]^ We further argue that conclusions from such studies may contribute unfairly to evidence, because this does not reflect usual practice, where expectant management beyond 42+6 GW is close to non-existent. All of the above mentioned systematic reviews by Wennerholm *et al.*,^[@R36]^ Gulmezoglu *et al.*,^[@R35]^ and Caughey *et al.*^[@R6]^ include studies with excessively long expectant management, e.g. one of the studies weighting the most in the systematic reviews uses expectant management until 44+0 GW.^[@R28]^

Regarding temporal criteria, the cited reviews included studies dating back to the 1960s and 1970s. At this time, fetal surveillance was less developed, induction agents were different from today, and both induction and CS rates were much lower. Caughey *et al.* describes restriction of studies to include only those "published from 1966 and beyond to represent modern obstetric practice".^[@R6](p253)^ We do not agree with the authors and find that obstetric practice (e.g. induction agents, CS rates and possibilities of monitoring pregnancy and childbirth) has changed substantially since 1966. Further, population characteristics have changed over this time. One could ask if it is reasonable to base a contemporary guideline on studies that are 40--50 years old. We suggest not, and have restricted publication dates of included studies to the last 20 years. The price to pay is fewer studies but with greater relevance.

Regarding estimation of due date, when the aim is to compare policies for induction of labor according to gestational age, the estimation of due date is paramount, and, consequently, the methods for estimation should be comparable. Previous reviews included studies with varied methods for estimating due date. Since EDD tends to differ between early ultrasound estimation and calculation by last menstrual period, this approach introduces a possible bias source to the analysis. Hence, in the present review we restricted data to studies using early ultrasound estimation.

In the present review, we allowed only for generally known methods of induction to be included (prostaglandins, balloon, oxytocin and artificial rupture of membranes). Even so, the included studies use different induction agents, and, thus, the external validity may be compromised. Furthermore, it was not possible to stratify on parity or rupture of membranes due to lack of information in the studies, and hence, both might be relevant. These factors might bias the results and we suggest the clinicians and stakeholders look thoroughly into individual studies before making local recommendations.

As described in the Methods section, the analytical approach for comparing groups is crucial to obtain a realistic scope for deciding recommendations for low-risk pregnancies past due date.^[@R25]^ Two different courses of action were compared in the present review: an active induction regimen and an expectant management, and data were restricted to a maximum expectancy up to 42+6 GW, since this reflects common practice, due to the increased risk of adverse outcome beyond that point. Our data showed that when women in the expectant arm were left without induction during week 41+0--6, a large proportion (∼70%) did in fact go into spontaneous labor before induction was recommended.^[@R13],[@R33],[@R43]^ However, the cited systematic reviews include studies that failed to include this sizable group of women in their analysis.^[@R6],[@R35],[@R36]^ When those in the expectant arm who gave birth during week 41+0--6 are excluded from analysis, the expectant arm is composed only of those who have reached 42+0 GW of pregnancy without the spontaneous onset of labor. Pregnancies that last beyond 42+0 GW are beyond the normal range of gestational time and are associated with an increased risk of complications. Therefore, comparison of outcomes between an induction arm composed of low-risk, healthy women whose labor was induced at 41+0--6 GW, and an expectant arm composed of women who have reached 42+0 GW and are therefore at heightened risk of complications is likely to bias the results in favor of induction. The risks associated with expectant management are likely to be overestimated. The problem can be circumvented if the large group of women in the expectant arm who go into spontaneous labor before 42+0 GW are included. Then a more accurate comparison can be made as to the effects of induction 41+0--6 GW versus expectant management, which, as has been noted, will in many cases result in spontaneous onset of labor before 42+0 GW. Therefore, in the present review, we draw only upon studies that include data on all participants in the expectant arm, including those who give birth between 41+0--6 and 42+0 GW. This will more correctly reflect the implications of using the two different guidelines, induction versus expectant management, and is probably the explanation as to why we found an increase in CS when performing routine induction in 41+0--6 GW, while other reviews found otherwise. We hope that issuing this topic will make stakeholders or authors of guidelines more attentive to the methodologies of the studies on which their recommendations are based.

The main limitation in this review concerns the limited number of included studies. It would, however, not be appropriate to rely on studies that do not include the gestational weeks under investigation, are up to 50 years old, use different methods for estimation of due date, or exclude the vast majority of women that go into spontaneous labor under an expectant management of pregnancies. We discussed problems with the wide variations in current systematic reviews and described how we have attempted to overcome the problem by defining strict criteria for inclusion. This decision had a major implication concerning the power of our analysis, as only seven studies were found to be eligible. To summarize, as Greenhalgh states: "any numerical result, however precise, accurate, 'significant,' or otherwise incontrovertible, must be placed in the context of the painfully simple and often frustratingly general question which the review addressed".^[@R53](p.674)^ Also, we were only able to separate groups by the number of weeks, even though different regimens should ideally be compared according to single days. Some guidelines recommend that the women deliver before 42+0 GW, which means that induction is not initiated until 41+3--5 GW.^[@R18],[@R19]^ In practice, this implies that a considerable number of women will have time to go into spontaneous labor before reaching the time for recommended induction. As we compile data on a weekly basis, our findings may overestimate the effects regarding both benefits and harms if the groups in reality are only separated by a few days.

Finally, none of the studies included indicators of long-term effects on the child, such as cerebral palsy or hypoxic-ischemic encephalopathy. Therefore, we included pH \< 7.10 as the best available proxy measure for possible long-term offspring outcomes. This is a deviation from the original protocol.^[@R37]^

Conclusion
==========

The objective of this systematic review was to compare the effect of routine labor induction between one and two weeks past EDD to the practice of awaiting spontaneous onset of labor until two weeks past EDD. The review included seven primary studies. We found routine induction at 41+0--6 GW associated with a decreased risk of meconium stained amniotic fluid and oligohydramnios and with an increased risk of CS, labor dystocia, chorioamnionitis, precipitate labor, uterine rupture and low pH in the newborn. No conclusions could be drawn on perinatal death due to lack of statistical power. For perinatal outcomes, our findings largely support previous meta-analyses, except for perinatal death. For maternal outcomes (including outcomes related to the course of labor), routine induction was associated with several adverse outcomes, including an increased risk of CS, which is not in line with previous reviews. The current review used stricter inclusion criteria than most of the previous reviews, which is potentially the main reason for discrepancies from previous findings. These restrictions were applied in order to enhance the methodological quality and increase the relevance for contemporary maternity care. Our findings do not support the widespread use of induction prior to post-term, and they highlight the importance of discussing whether the threshold has been reached where risks related to the procedure of induction outweigh potential harms from the ongoing pregnancy, and whether induction of labor should be applied to large populations of low-risk women. If an intervention cannot demonstrate a positive association between higher intervention rates and an improved perinatal outcome, and evidence exists that the intervention itself may impose maternal and perinatal risks, it is normally decided to strive for the lowest intervention rates. In the case of routine induction prior to post-term, the challenge is how to prevent fetal demise leading to poor fetal outcome and in few occasions of fetal death. Nevertheless, one might ask if routine induction of labor on larger populations of healthy women and fetuses is the answer to this task, when -- as demonstrated in this review -- the intervention is associated with several iatrogenic effects.

Recommendations for practice
----------------------------

As much as the above discussion on research methodology and inclusion criteria in systematic reviews may appear as a purely academic one, it affects clinical daily life. Since clinical guidelines mainly rely on systematic reviews, and since systematic reviews are justified by their ability to weigh and sum up relevant research on a given subject, such discussions are highly relevant for practice. In the current review, we used stricter criteria for inclusion, and we found that doing so changed the conclusions from previous reviews. We suggest increased awareness of inclusion criteria in systematic reviews as they can reflect contemporary clinical practice, and the findings can be applied to guidelines and practice. We also suggest that clinicians and stakeholders look into original individual studies before making local guidelines.

The current review revealed several adverse outcomes associated with routine induction, which may not be prioritized in the information given before consent to labor induction.^[@R54]^ It is of the utmost importance that women are thoroughly informed about benefits and harms before making their decision on induction by routine, as described in general requirements of health legislations. In order to present balanced and understandable information, absolute numbers may also be needed. The current review presents absolute numbers to raise awareness of the communication of scientific evidence among users and policy makers. As health professionals, we should be aware that our choice of which risk measures to present works as a tool by which we can influence people\'s decisions regarding routine induction or not. We suggest that future research and clinical practice include absolute numbers and absolutes risks in addition to the usual relative estimates.

According to Joanna Briggs Institute Grades of Recommendations, our findings do not support the obstetric practice for low-risk pregnancies with routine labor induction at 41+0 to 41+6 GW when compared to expectant management (routine labor induction at 42+0 to 42+6 GW), because desirable effects do not appear to outweigh undesirable effects of such practice. There is not strong evidence supporting its use, and there does not seem to be any resource benefits from following this practice (Grade B). Values, preferences and the patient experience have not been taken into account.

Recommendations for research
----------------------------

The current review revealed important methodological weaknesses in existing systematic reviews on labor induction prior to post-term. One important problem is the use of studies with improper gestational timeframes in the comparison group. Another problem is the use of old studies. Obstetric practice (fetal surveillance, induction agents, clinical procedures, intervention rates etc.) as well as population characteristics have changed substantially since the 1960s--1980s. It is questionable whether findings from studies of such age can be extrapolated to a contemporary setting. A third problem is the use of studies with different methods for estimating due date and/or different induction agents within or across studies. The above aspects are all likely to bias the conclusions reported in some of the key scientific papers behind existing clinical guidelines. In the current review, we used stricter criteria for inclusion of studies in order to overcome some of the above flaws. This approach has resulted in a generally positive assessment of the methodological quality of the included studies, but the consequence has been a smaller sample size than in most previous reviews. We suggest that systematic reviews, with all their best efforts to promote evidence-based decision-making, should be studied carefully by stakeholders for external validity, since only few studies in a review may be relevant for the given clinical decision-making process.

The review process revealed a focus on few, selected outcomes in labor induction studies. Cesarean section and perinatal death have gained much focus so far, while e.g. hyperstimulation, tachysystole, and precipitate labor are understudied. This is of interest, because routine induction is performed on a healthy low-risk population, and in such cases, only a low risk of iatrogenic effects is usually accepted. We also found that several central aspects were generally not covered or inadequately accounted for in existing research. For example, it was not possible to evaluate long-term effects, the need for care, economic resources, or the experience of birth when artificially induced compared to being in a tight surveillance regimen awaiting spontaneous onset of labor. Long-term effects in the child may include cerebral palsy, brachial plexus injury, or hypoxic-ischemic encephalopathy. Even though pH \< 7.10 and resuscitation may be indicators for such long-term effects, we suggest that future studies include a broad selection of both short- and long-term outcomes when evaluating the procedure of routine induction prior to post-term.

The current review revealed a 20% increase in inductions when using a guideline of recommending induction 41+0--6 GW, which affects workload in the labor ward. Inductions require extra attention compared to spontaneously initiated deliveries, and these resources may be drawn away from other laboring women. We suggest that future studies focus on economic consequences of new routines as well as health outcomes related to busy staff.
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Appendix I: Individual search strategies
========================================

**PubMed (pubmed.gov):** searched on 18/06/2018

![](jbisris-17-170-g007){#d35e2392}

**CINAHL (EBSCO):** searched on 18/06/2018

![](jbisris-17-170-g008){#d35e2398}

**Embase (Elsevier):** searched on 18/06/2018

![](jbisris-17-170-g009){#d35e2404}

**Scopus (Elsevier):** searched on 18/06/2018

![](jbisris-17-170-g010){#d35e2410}

**Swemed+:** searched on 15/03/2018

![](jbisris-17-170-g011){#d35e2416}

**POPLINE (K4health):** searched on 15/03/2018

![](jbisris-17-170-g012){#d35e2423}

**Cochrane Library:** searched on 18/06/2018

![](jbisris-17-170-g013){#d35e2429}

**TRIP Medical Database:** searched on 14/03/2018

![](jbisris-17-170-g014){#d35e2435}

**Current Controlled Trials:** searched on 14/03/2018

![](jbisris-17-170-g015){#d35e2441}

**Web of Science:** searched on 14/03/2018

![](jbisris-17-170-g016){#d35e2447}

**MedNar:** searched on 15/03/2018

![](jbisris-17-170-g017){#d35e2454}

**Google Scholar:** searched on 15/03/2018

![](jbisris-17-170-g018){#d35e2460}

**OpenGrey:** searched on 15/03/2018

![](jbisris-17-170-g019){#d35e2466}

**ProQuest Nursing and Allied Health Source:** searched on 20/03/2018

![](jbisris-17-170-g020){#d35e2472}

National Institute for Health and Care Excellence, World Health Organization, Royal College of Obstetricians and Gynaecologists, American College of Obstetricians and Gynecologists, and Society of Obstetricians and Gynaecologists of Canada. Searched on 15/03/2018

![](jbisris-17-170-g021){#d35e2476}

Appendix II: General characteristics of included studies
========================================================

![](jbisris-17-170-g022){#d35e2481}

![](jbisris-17-170-g023){#d35e2483}

![](jbisris-17-170-g024){#d35e2485}

![](jbisris-17-170-g025){#d35e2487}

![](jbisris-17-170-g026){#d35e2489}

![](jbisris-17-170-g027){#d35e2491}

![](jbisris-17-170-g028){#d35e2493}

Appendix III: Details on comparison groups in included studies
==============================================================

![](jbisris-17-170-g029){#d35e2498}

![](jbisris-17-170-g030){#d35e2500}

Appendix IV: Outcome measures in included studies
=================================================

![](jbisris-17-170-g031){#d35e2505}

Appendix V: Excluded studies
============================

![](jbisris-17-170-g032){#d35e2510}

Appendix VI: Meta-analyses
==========================

***Perinatal outcomes***

***Analysis 1. Admission to neonatal intensive care unit. Quasi- or randomized studies***

![](jbisris-17-170-g033){#d35e2523}

***Analysis 2. Apgar score (less than 7 after 5 minutes). Quasi- or randomized studies***

![](jbisris-17-170-g034){#d35e2529}

***Analysis 3. Macrosomia \>4500 g. Quasi- or randomized studies***

![](jbisris-17-170-g035){#d35e2535}

***Analysis 4. Meconium aspiration syndrome. Quasi- or randomized studies***

![](jbisris-17-170-g036){#d35e2541}

***Analysis 5. Meconium stained amniotic fluid. Quasi- or randomized studies***

![](jbisris-17-170-g037){#d35e2548}

***Analysis 6. Perinatal death. Quasi- or randomized studies***

![](jbisris-17-170-g038){#d35e2554}

***Analysis 7. pH \<7.10. Quasi- or randomized studies***

![](jbisris-17-170-g039){#d35e2560}

***Analysis 8. Shoulder dystocia. Quasi- or randomized studies***

![](jbisris-17-170-g040){#d35e2566}

***Maternal outcomes***

***Analysis 9. Cesarean Section. Quasi- or randomized studies***

![](jbisris-17-170-g041){#d35e2576}

***Analysis 10. Cesarean Section for failure to progress. Quasi- or randomized studies***

![](jbisris-17-170-g042){#d35e2583}

***Analysis 11. Cesarean Section for fetal distress. Quasi- or randomized studies***

![](jbisris-17-170-g043){#d35e2589}

***Analysis 12. Instrumental vaginal delivery. Quasi- or randomized studies***

![](jbisris-17-170-g044){#d35e2595}

***13. Vaginal delivery. Quasi- or randomized studies***

![](jbisris-17-170-g045){#d35e2601}
